Background: Human immunodeficiency virus (HIV) infection is associated with an increased risk of aggressive lymphoma, especially diffuse B cell lymphoma (DLBCL). We aimed to analyze characteristics and outcomes of DLBCL in HIV-associated patients.
Methods: We retrospectively studied HIV-infected patients with DLBCL since 2011. Data on HIV infection and lymphoma characteristics, treatment and outcome were retrieved and analyzed.
Results: In 53 patients with HIV-associated DLBCL, most patients had frequent bad performance status (PS) (74%), elevated LDH level (94%), B symptoms (69%), advanced Ann Arbor (75%), bulky tumor (72%) and extra-nodal involvement (68%) at diagnosis. The median CD4 T cell count was 175/μl, and 17 patients were already on cART treatment. Plasma EBV DNA was detectable in 18 patients (53%, 18/34). Of the patients evaluated at the end of treatment, 21 (64%) achieved CR, 1 (3%) achieved PR and 6 (18%) experienced progressive disease. The 2-year progression free survival (PFS) was 50% and overall survival (OS) rate was 60%. Factors associated with poor PFS in univariate analysis were unfavorable PS, high IPI score and detectable plasma EBV load. High IPI and detectable EBV load correlated with worse OS. However, only detectable plasma EBV load was the independent factor of poor prognosis for PFS (HR: 14.46, 95% CI [2.57-81.50]) and OS (HR: 7.47, 95% CI [1.48-37.59]) in a multivariate Cox regression model.
Conclusions: In our population, HIV-associated DLBCL still presented aggressive characteristics and poor survival outcomes. Plasma EBV DNA could be used as a prognostic factor in HIV-infected DLBCL.